[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652518":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":25,"centralContacts":30,"locations":25,"responsibleParty":36,"collaborators":25,"id":38,"slug":39,"hasResults":40,"nctId":41,"briefTitle":42,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":40,"sex":46,"minAge":47,"maxAge":25,"enrollmentInfo":48,"targetDuration":25,"studyType":51,"phases":52,"briefSummary":54,"conditions":55,"keywords":25,"overallStatus":57,"whyStopped":25,"lastUpdateSubmitDate":58,"lastUpdatePostDateStruct":59,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":25},{"fullName":5,"class":6},"argenx","INDUSTRY",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"ARGX-121","EXPERIMENTAL","Participants will receive ARGX-121 in subcutaneous injections during the double blinded treatment period and active only treatment periods (Total of 52 weeks)",[13],"Biological: ARGX-121",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo followed by ARGX-121","PLACEBO_COMPARATOR","Participants receive placebo for the double-blinded period of 24 weeks, followed by subcutaneous injections of ARGX-121 during the active only treatment period of 28 weeks.",[13,19],"Biological: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"BIOLOGICAL","Subcutaneous Injection of ARGX-121",[9,15],null,{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":25},"Placebo","Subcutaneous Injection of Placebo",[15],[31],{"name":32,"role":33,"phone":34,"phoneExt":25,"email":35},"Sabine Coppieters, MD","CONTACT","857-350-4834","Clinicaltrials@argenx.com",{"type":37,"investigatorFullName":25,"investigatorTitle":25,"investigatorAffiliation":25,"oldNameTitle":25,"oldOrganization":25},"SPONSOR","100652518","phase-2-a-study-to-evaluate-the-effect-of-argx-121-on-the-change-in-proteinuria-in-adult-participants-with-igan-100652518",false,"NCT07773727","A Study to Evaluate the Effect of ARGX-121 on the Change in Proteinuria in Adult Participants With IgAN","A Phase 2, Multicenter, Randomized, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of ARGX-121 SC in Adult Participants With Primary IgA Nephropathy","Verdant","Inclusion Criteria:\n\n* Males and females (not pregnant)\n* At least 18 years old\n* Clinically diagnosed with IgAN with biopsy confirmation\n\nExclusion Criteria:\n\n* Diagnosis of another autoimmune disease or known medical condition that would interfere with accurate assessment of clinical systems of IgAN\n* Has secondary form of IgAN leading to IgA deposits\n* History of Malignancy\n* Active infection of concern\n* Recent Major surgery or organ transplant","ALL","18 Years",{"count":49,"type":50},120,"ESTIMATED","INTERVENTIONAL",[53],"PHASE2","The study will assess how ARGX-121 affects immunoglobulin A nephropathy (IgAN) disease outcomes, such as renal function, how it is distributed and eliminated from the body, and how the immune system responds in adults with IgAN.\n\nWhile in the study, participants will continue to receive their usual medical care and medications for IgA nephropathy, unless the study doctor confirms otherwise.\n\nThe study will include a double blinded period, followed by an active drug period, and conclude with a follow up period. The total study duration for participants will be approximately 72 weeks, with a maximum of 52 weeks on ARGX-121.",[56],"Immunoglobulin A Nephropathy (IgAN)","NOT_YET_RECRUITING","2026-08-14",{"date":60,"type":61},"2026-08-19","ACTUAL",{"date":63,"type":50},"2026-10-15",{"date":65,"type":50},"2030-02-18",{"name":5,"class":6}]